Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Director · Chief Executive Officer | August 03, 2026 | August 05, 2026 |
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,968 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 6,551 · Balance 284,968 F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
ProMIS Neurosciences Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 5,500 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 5,500 · Balance 5,500 F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 11,000 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 11,000 · Balance 11,000 F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:07 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,551 | $1.65 | $10,809.15 |
DisclosureSEC source: 0001628280-26-053505 · wk-form4_1785964039.xml · nonDerivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,968 F1 · price: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:31 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 11,000 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065763 · tm2615475-3_4seq1.xml · derivative · entry 2 Mandel-Brehm Josh · CIK 0001927058 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2036-05-20 F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:31 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 5,500 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065763 · tm2615475-3_4seq1.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Shares · 5,500 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:46 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 580,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001927058-26-000002 · wk-form4_1775249179.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,000 Underlying: Common Stock · 580,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| December 11, 2025 Filed Dec 22, 2025 22:41 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001927058-25-000004 · wk-form4_1766443271.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2035-12-10 F1 · derivative.exercise_date: This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:23 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,060 | $1.65 | $9,999.00 |
DisclosureSEC source: 0001927058-25-000002 · wk-form4_1757622219.xml · nonDerivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,417 F1 · price: On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:23 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001374339-25-000006 · primary_doc.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:06 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001628280-25-016481 · wk-form4_1743710748.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 21:45 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 6,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-108699 · tm2426125-1_4seq1.xml · derivative · entry 2 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 605 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · price: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 21:45 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-108699 · tm2426125-1_4seq1.xml · nonDerivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · price: On October 15, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 22:38 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-24-106767 · tm2425760-2_4seq1.xml · derivative · entry 1 Mandel-Brehm Josh · CIK 0001927058 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-10-03 F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.